Current Projects

Active Projects on the 3T Siemens Scanner as of July 2021.

Click on a researcher’s name to learn more.

Dr. Jiwon OhThe Canadian Proactive Cohort Study for People Living with Multiple Sclerosis (CANPROCO)Neurology
Dr. Tom SchweizerAthlete traumatic brain injury, concussion and fMRINeurology
Dr. Jiwon OhQuantitative Spinal Cord MRI as a Biomarker of Treatment Response in MS: A Prospective StudyNeurology
Dr. Tom SchweizerInvestigating driving performance and underlying neural networks of aging cohorts and individuals with mild cognitive impairment and Alzheimer's diseaseNeurology
Dr. Sakina RizviA dimensional approach to evaluate reward processing in major depressive disorder before and after treatment with desveniafaxineNeurology
Dr. Tom SchweizerUnderstanding how disorders of the brain affect driving abilities: An fMRI driving-simulator studyNeurology
Dr. Sidney KennedyIdentification of reward-based markers for risk of depression following mild traumatic brain injuryNeurology
Dr. Sakina RizviIdentifying the neural basis of capability for suicideNeurology
Dr. Jiwon OhQuantitative Spinal Cord MRI in Radiologically Isolated Syndrome: A Prospective StudyNeurology
Dr. Sakina RizviPain, Reward, Attention and Neurocircuitry: Biomarkers of SuicidalityNeurology
Dr. Iqwal MangatOCEAN trial: Optimal anticoagulation for enhanced risk patient path-catheter ablation for atrial fibrillationNeurology
Dr. Vinod Chandran (UHN)Identifying Biomarkers for Joint Damage in Early Psoriatic ArthritisMuskuloskeletal
Dr. Anish KirpalaniA pilot study to access the role of magnetic resonance imaging in assessing kidney transplant injury following kidney transplantationNephrology
Dr. Corinne FischerA Phase III Multicenter randomized double-blind placebo-controlled parallel-group efficacy and safety study of Gantenerumab in patients with early (Prodromal to Mild) Alzheimer’s DiseaseNeurology
Dr. Corinne FischerValidation of ocular measures as potential biomarkers for early detection of brain amyloid and neurodegenerationNeurology
Dr. Anish KirpalaniFunctional Evaluation of Transplanted Kidneys in Outpatient Setting with Diffusion Weighted Magnetic Resonance Imaging and MR ElastographyNephrology
Dr. Anish KirpalaniOPTIMUM MRI PROTOCOL: Magnetic Resonance Imaging in Volunteers to Establish Optimum ProtocolsBody
Dr. David JenkinsMRI Enhanced dietary portfolio, exercise and heart riskBody, Cardiology
Jefferson WilsonNatural History of Mild Degenerative Cervical Myelopathy: an observational studyNeurology
Dr. Kim ConnellyRandomized double blind placebo controlled trial of Statins for the Primary Prevention of Heart Failure in patients wit cancer recieving anthracycline base chemotherapy - Pilot StudyCardiology
Dr. Kim ConnellyThe impact of diabetic microvascular dysfunction on late major adverse cardiac events post non-ST elevation acute coronary syndromeCardiology
Dr. Kim ConnellyAcute and chronic effects of Ivabradine upon cardiac structure and function and cerebral blood flowCardiology
Mohammed Al-omranStudy of Lipids Inside the Carotid with Evolocumab: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology prior to Carotid End ArterectomyNeurology
John GrahamSPYRAL PIVOTALBody
Dr. Lisa HicksAn Open-Label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic MastocytosisBody
Jerry Teitel Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (BeneGene-2)Muskuloskeletal
Dr. Peter VadasA 3-Part randomized double-blind placebo-controlled Phase 2 study to evaluate safety and efficacy of Avapritinib (BLU-285) a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately controlled with Standard TherapyNeurology
Dr. Sunit DasAdvanced MRI to Detect Stem cell Niches in GlioblastomaNeurology
Daniel SelchenMultiple Sclerosis: Safety and Efficacy Study of Elezanumab (ABT-555) in Progressive Forms of Multiple SclerosisNeurology
Daniel SelchenMultiple Sclerosis: Safety and Efficacy Study of Elezanumab (ABT-555) in Relapsing Forms of Multiple SclerosisNeurology
Daniel SelchenA Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects with Relapsing-Remitting Multiple Sclerosis Switching from Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID TreatmentNeurology
Dr. Magdy ElkhashabA Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic SteatohepatitisHepatology
Dr. Magdy ElkhashabA Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-316 (resmetirom) in Patients with Non-Alcoholic Streatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic DecompensationHepatology
Dr. Magdy ElkhashabA randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (TANDEM)Hepatology
Dr. Magdy ElkhashabA Phase 2, randomized, double-blind, double dummy, placebo-controlled, dose-ranging, dose-finding, parellel group study to assess efficacy and safety of PF-06865571 (OGAT21) alone and when coadministered with PF-05221304 (ACCI) in adult participants with biopsy-confirmed nonalcoholic steatohepatitis and fibrosis stage 2 or 3Hepatology
Reza VosoughiA Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab AdministrationNeurology
Reza VosoughiAn Open-label, Single-arm 4-year study to evaluate effectiveness and safety of Ocrelizumab treatment in Patients with Progressive Multiple SclerosisNeurology
Reza VosoughiA Phase III multicentre randomized parallel-group double blinded placebo controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary Progressive Multiple Sclerosis: ORATORIO TrialNeurology
Dr. Iqwal MangatThe Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial: OCEANCardiology
Michael CuisimanoValidation of non-invasive rapid eye movements measurement as screening tool for mild traumatic brain injuryNeurosurgery
Dr. Sunit DasAdvanced MRI to Detect Stem Cell Niches in GlioblastomaNeurosurgery
Ronald Goldberg (LMC)A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Dose Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF 05221304 (ACCi) in Adult Participants with Biopsy Confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3Hepatology
Alex Abitol (LMC)A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Dose Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF 05221304 (ACCi) in Adult Participants with Biopsy Confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3Hepatology
Harpreet Bajaj (LMC)Novartis Pharmaceuticals - Canada - CLJN452D12201C, A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral therapy, compared to each monotherapy, for treatment of adult patients withtropifexor (LJN452) & licogliflozin (LIK066) combination nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE) (Pro00040326)Body

X